肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2010年
8期
526-529
,共4页
徐敏%郭灵%廖家华%孙蕊%林焕新
徐敏%郭靈%廖傢華%孫蕊%林煥新
서민%곽령%료가화%손예%림환신
鼻咽肿瘤%放射治疗,计算机辅助%药物疗法,联合%预后
鼻嚥腫瘤%放射治療,計算機輔助%藥物療法,聯閤%預後
비인종류%방사치료,계산궤보조%약물요법,연합%예후
Nasopharyngeal neoplasms%Radiotherapy,computer-assisted%Drug therapy,combination%Prognosis
目的 回顾分析T3N0-1M0期鼻咽癌患者临床资料,探讨单纯放射治疗与同期放化疗两种治疗方式与预后的关系.方法 中山大学肿瘤防治中心2004年1月至12月收治的经病理学证实的初治鼻咽癌患者781例,均有完整鼻咽和颈部MRI资料,且均无远处转移.按照2008中国鼻咽癌分期标准重新分期,82例行单纯放疗或同期放化疗的T3N0～1M0期患者入组,分为单纯放疗(A组)46例,同时期放化疗(B组)36例.结果 两组患者的临床资料具有可比性,单因素分析显示A组和B组的5年总生存(OS)率分别为93.5%和100%(P=0.046),5年无瘤生存(DFS)率分别为85.2%和91.7%(P=0.498).N分期是鼻咽癌DFS的影响凶素(P=0.026).分层分析显示:T3N0M0期患者A组和B组5年OS率分别为94.7%和100%(P:0.432);T3N1M0期A组和B组5年OS率分别为92.6%和100%(P=0.066);T3N1M0期A组和B组5年DFS率分别为73.7%和89.3%(P=0.244).多凶素分析显示,同期放化疗不是T3N0～M0期鼻咽癌患者OS的独立预后因素(HR=0.019;95%C/0～21.793),N分期不是影响T3N0～1M0期鼻咽癌患者DFS的独立预后因素(HR=0.203;95%CIO.135～1.231×104).结论 T3N0M0期患者同期放化疗与单纯放疗疗效无差异,T3N1M0期患者行同期放化疗能否改善生存有待进一步研究.
目的 迴顧分析T3N0-1M0期鼻嚥癌患者臨床資料,探討單純放射治療與同期放化療兩種治療方式與預後的關繫.方法 中山大學腫瘤防治中心2004年1月至12月收治的經病理學證實的初治鼻嚥癌患者781例,均有完整鼻嚥和頸部MRI資料,且均無遠處轉移.按照2008中國鼻嚥癌分期標準重新分期,82例行單純放療或同期放化療的T3N0～1M0期患者入組,分為單純放療(A組)46例,同時期放化療(B組)36例.結果 兩組患者的臨床資料具有可比性,單因素分析顯示A組和B組的5年總生存(OS)率分彆為93.5%和100%(P=0.046),5年無瘤生存(DFS)率分彆為85.2%和91.7%(P=0.498).N分期是鼻嚥癌DFS的影響兇素(P=0.026).分層分析顯示:T3N0M0期患者A組和B組5年OS率分彆為94.7%和100%(P:0.432);T3N1M0期A組和B組5年OS率分彆為92.6%和100%(P=0.066);T3N1M0期A組和B組5年DFS率分彆為73.7%和89.3%(P=0.244).多兇素分析顯示,同期放化療不是T3N0～M0期鼻嚥癌患者OS的獨立預後因素(HR=0.019;95%C/0～21.793),N分期不是影響T3N0～1M0期鼻嚥癌患者DFS的獨立預後因素(HR=0.203;95%CIO.135～1.231×104).結論 T3N0M0期患者同期放化療與單純放療療效無差異,T3N1M0期患者行同期放化療能否改善生存有待進一步研究.
목적 회고분석T3N0-1M0기비인암환자림상자료,탐토단순방사치료여동기방화료량충치료방식여예후적관계.방법 중산대학종류방치중심2004년1월지12월수치적경병이학증실적초치비인암환자781례,균유완정비인화경부MRI자료,차균무원처전이.안조2008중국비인암분기표준중신분기,82례행단순방료혹동기방화료적T3N0～1M0기환자입조,분위단순방료(A조)46례,동시기방화료(B조)36례.결과 량조환자적림상자료구유가비성,단인소분석현시A조화B조적5년총생존(OS)솔분별위93.5%화100%(P=0.046),5년무류생존(DFS)솔분별위85.2%화91.7%(P=0.498).N분기시비인암DFS적영향흉소(P=0.026).분층분석현시:T3N0M0기환자A조화B조5년OS솔분별위94.7%화100%(P:0.432);T3N1M0기A조화B조5년OS솔분별위92.6%화100%(P=0.066);T3N1M0기A조화B조5년DFS솔분별위73.7%화89.3%(P=0.244).다흉소분석현시,동기방화료불시T3N0～M0기비인암환자OS적독립예후인소(HR=0.019;95%C/0～21.793),N분기불시영향T3N0～1M0기비인암환자DFS적독립예후인소(HR=0.203;95%CIO.135～1.231×104).결론 T3N0M0기환자동기방화료여단순방료료효무차이,T3N1M0기환자행동기방화료능부개선생존유대진일보연구.
Objective To retrospectively analyze the data of patients with T3N0-1M0 nasopharyngeal carcinoma (NPC) who underwent radiotherapy (RT) alone or concurrent chemoradiotherapy (CCRT), and to investigate the relationship between therapeutic modality and prognosis. Methods From January 2004 to December 2004, 781 patients with biopsy-proven newly diagnosed non-metastatic NPC were analyzed in Sun Yat-Sen University Cancer Center, who had MRI data of nasopharynx and neck. With restaged based on the Chinese 2008 staging system, 82 cases of T3N0-1M0 patients who were treated by RT alone or CCRT were enrolled. They were divided into group A (46 cases, RT) and group B (36 cases, CCRT). Results The clinical data was comparable between the two groups. The 5-year overall survival rate (OS) was 93.5 % (group A) and 100 % (group B)(P =0.046), while the 5-year disease-free survival rate (DFS) was 85.2 % (group A) and 91.7 % (group B) (P =0.498). N-Staging was the factor affecting the DFS. Stratified analysis showed that the 5-year OS of T3N0M0 patients was 94.7 % (group A) and 100 % (group B) (P =0.432), those of T3N1M0 patients were 92.6 %(group A) and 100 %(group B) (P =0.066), while the 5-year DFS was 73.7 % (group A) and 89.3 % (group B) (P =0.244). Multifactor analysis showed that CCRT was not the independent factor affecting the OS(HR =0.019; 95 % CI, 0 to 21.793), and N-stage was not the independent factor affecting the DFS (HR = 0.203; 95 % CI, 0.135 to 1.231×104). Conclusion For T3N0M0, NPC patients, CCRT is not superior to RT alone. Whether CCRT can improve survival of T3N1M0 NPC patients needs further study.
